In One Timeline

Ozempic: From Lizard Venom to $30 Billion (1986-2026)

Semaglutide sales went from near-zero in 2018 to roughly $30 billion a year - one of the fastest revenue ramps in pharma history. But the science behind the 'overnight miracle' is ~30 years old, and starts with a peptide isolated from Gila monster venom in 1992. Plotted to scale: decades of quiet biology on the left, the money spike on the right, and the US-vs-world price gap as the twist.

—credits6sourcesAll episodes
No third-party image credits. This episode's visuals are original charts/animations and AI-generated b-roll — nothing that requires attribution.

Data sources & references

01Novo Nordisk — SEC 6-K annual results
02Eli Lilly — SEC 10-K (Mounjaro / Zepbound sales)
03U.S. FDA — Drugs@FDA approvals database
04Eng et al. 1992 — exendin-4 from Gila monster venom (J. Biol. Chem.)
05Peterson-KFF Health System Tracker — international price comparison
06JAMA Network Open 2024 — estimated production-cost analysis